# The FDA's Oncologic Drugs Advisory Committee (ODAC) voted six ​to three against camizestrant.

*biotech · news · 2026-05-01 · Reuters*

## Key points

- The FDA panel voted 6-3 against camizestrant due to concerns with its trial design, not efficacy.
- Analysts believe camizestrant could still gain FDA approval based on data from other studies.
- Bernstein lowered AstraZeneca's target price to 18,600 pence, citing limited immediate stock upside.
- Camizestrant represents only about 1% of AstraZeneca's overall valuation, per JPMorgan.

**Companies:** AstraZeneca
**Countries:** United States, United Kingdom, India

[Read the full story on Reuters](https://www.reuters.com/sustainability/boards-policy-regulation/astrazeneca-shares-drop-after-us-regulatory-panel-votes-against-breast-cancer-2026-05-01/)

---

Canonical: https://newsio.io/n/6f63dcae-b4c2-42fc-be9c-f595d3945f3f/the-fdas-oncologic-drugs-advisory-committee-odac-voted-six-to-three-against-cami
Summarized by Newsio from Reuters. https://newsio.io/how-it-works